Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28801393 | 0.89 | HSD17B10 (0.49) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL2589891 | 0.86 | HSD17B10 (0.56) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL30001924 | 0.86 | HSD17B10 (0.56) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL1663175 | 0.85 | HSD17B10 (0.60) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL7786691 | 0.83 | HSD17B10 (0.62) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL2205749 | 0.83 | HSD17B10 (0.62) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL868877 | 0.83 | HSD17B10 (0.62) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL4014324 | 0.83 | HSD17B10 (0.53) | HSD17B10KMT2AVCAM1ALDH1A1CYP1A2 | |
| SCHEMBL260788 | 0.82 | CYP1A2 (0.51) | HSD17B10ALDH1A1CYP1A2LMNAGPR35 | |
| SCHEMBL29367937 | 0.82 | CYP1A2 (0.51) | HSD17B10ALDH1A1CYP1A2LMNAGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103468-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2026-04-16 | — | — | US | disclosed |
| US-12398142-B2 | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases | EMORY UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| CN-119948028-A | Condensed-cyclic compound, pharmaceutical composition and application thereof | 海南先声再明医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12275686-B2 | NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof | SOUTHEAST UNIVERSITY (CN) | 2025-04-15 | — | — | US | disclosed |
| CN-116675620-B | NO donor compound, preparation method, pharmaceutical composition and application thereof | 东南大学 | 2025-01-10 | — | — | CN | disclosed |
| EP-4484409-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Southeast University (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240409500-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SOUTHEAST UNIVERSITY (CN) | 2024-12-12 | — | — | US | disclosed |
| WO-2024067792-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 海南先声再明医药股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-116675620-A | NO donor compound, preparation method, pharmaceutical composition and application thereof | 东南大学 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023160344-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 东南大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-1170822-C | Imidazole compounds and pharmaceutical use thereof | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| CN-1335837-A | Imidazole compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1142879-A1 | IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | HSD17B10 1262/4885KMT2A 1218/4885VCAM1 707/4885 |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | HSD17B10 2591/4885KMT2A 1625/4885VCAM1 1623/4885 |
| US-12275686-B2 | NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof | HIF1A, NOS1, NOS2 | HSD17B10 871/4885KMT2A 2397/4885VCAM1 1030/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | HSD17B10 652/4885KMT2A 1587/4885VCAM1 1709/4885 |
| US-20240409500-A1 | NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | HIF1A, NOS1, NOS2 | HSD17B10 871/4885KMT2A 2397/4885VCAM1 1030/4885 |
| US-20260103468-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | NR3C2, CYP11B1, CYP11B2 | HSD17B10 41/4885KMT2A 3270/4885VCAM1 2073/4885 |
| US-12398142-B2 | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases | ABL2, ABL1, FYN | HSD17B10 4283/4885KMT2A 784/4885VCAM1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.